NCT06657079View on ClinicalTrials.gov

A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions
ARDSPrevention and Control
Interventions
DRUG

combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days

combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days

DRUG

Placebo

Saline inhaler

Trial Locations (1)

Unknown

Mashtoul El Souq governmental hospital (50 beds), Sharkia, Egypt, Cairo

All Listed Sponsors
collaborator

Badr University

OTHER

lead

Damanhour University

OTHER

NCT06657079 - A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS | Biotech Hunter | Biotech Hunter